RACA
Therapeutics Acquisition Corp. [RACA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RACA Stock Summary
In the News
POINT Biopharma Debuts as Publicly Traded Next-Generation Radiotherapeutics Company
Common stock to commence trading on the Nasdaq Capital Market on July 1, 2021 under the ticker symbol “PNT”
Research Alliance Corp. I Announces Effectiveness of Registration Statement for Proposed Business Combination with POINT
BOSTON--(BUSINESS WIRE)--Therapeutics Acquisition Corp, d/b/a Research Alliance Corp. I, a Delaware corporation (“the Company”) (Nasdaq: RACA) announced today that its registration statement on Form S-4 (File Number 333-254600) (as amended, the “Registration Statement”), relating to the previously announced business combination (the “Business Combination”) with POINT Biopharma Inc. (“POINT”), has been declared effective by the U.S. Securities and Exchange Commission (“SEC”) and that it will com
POINT Biopharma Announces First Patients Dosed in Phase 3 Study of PNT2002 for mCRPC
INDIANAPOLIS--(BUSINESS WIRE)--POINT Biopharma Inc. (POINT), a global radiopharmaceutical company dedicated to successfully delivering precision radioligand therapy to cancer patients, today announced that it has successfully dosed multiple patients in its Phase 3 SPLASH study evaluating the efficacy of PNT2002, the Company's investigational 177Lu-PSMA targeted radioligand therapy for patients with PSMA expressing metastatic castration resistant prostate cancer (mCRPC) who are not eligible for
POINT Biopharma Announces First Patients Dosed in Phase 3 Study of PNT2002 for mCRPC
INDIANAPOLIS, June 04, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Inc. (POINT), a global radiopharmaceutical company dedicated to successfully delivering precision radioligand therapy to cancer patients, today announced that it has successfully dosed multiple patients in its Phase 3 SPLASH study evaluating the efficacy of PNT2002, the Company's investigational 177Lu-PSMA targeted radioligand therapy for patients with PSMA expressing metastatic castration resistant prostate cancer (mCRPC) who are not eligible for chemotherapy.
RACA Financial details
RACA Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2020-12-31
| Metric | History | 2020-12-31 |
|---|---|---|
| 2.02K | ||
| Revenue per share | 0 | |
| Net income per share | 0 | |
| Operating cash flow per share | 0 | |
| Free cash flow per share | 0 | |
| Cash per share | 0 | |
| Book value per share | 0 | |
| Tangible book value per share | 0 | |
| Share holders equity per share | 0 | |
| Interest debt per share | 0 | |
| Market cap | 0 | |
| Enterprise value | -1.09M | |
| P/E ratio | 0 | |
| Price to sales ratio | 0 | |
| POCF ratio | 0 | |
| PFCF ratio | 0 | |
| P/B Ratio | 0 | |
| PTB ratio | 0 | |
| EV to sales | 0 | |
| Enterprise value over EBITDA | 0 | |
| EV to operating cash flow | 0 | |
| EV to free cash flow | 0 | |
| Earnings yield | 0 | |
| Free cash flow yield | 0 | |
| Debt to equity | 0 | |
| Debt to assets | 0 | |
| Net debt to EBITDA | 0 | |
| Current ratio | 10.2 | |
| Interest coverage | 0 | |
| Income quality | 0 | |
| Dividend Yield | 0 | |
| Payout ratio | 0 | |
| Sales general and administrative to revenue | 0 | |
| Research and developement to revenue | 0 | |
| Intangibles to total assets | 0 | |
| Capex to operating cash flow | 0 | |
| Capex to revenue | 0 | |
| Capex to depreciation | 0 | |
| Stock based compensation to revenue | 0 | |
| Graham number | 0 | |
| ROIC | 0 | |
| Return on tangible assets | 0 | |
| Graham Net | 0 | |
| Working capital | 1.08M | |
| Tangible asset value | 132.04M | |
| Net current asset value | -3.67M | |
| Invested capital | 0 | |
| Average receivables | 0 | |
| Average payables | 0 | |
| Average inventory | 0 | |
| Days sales outstanding | 0 | |
| Days payables outstanding | 0 | |
| Days of inventory on hand | 0 | |
| Receivables turnover | 0 | |
| Payables turnover | 0 | |
| Inventory turnover | 0 | |
| ROE | 0 | |
| Capex per share | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2021-06-30 for Q2
| Metric | History | 2020-04-30 | 2020-06-30 | 2021-03-31 | 2021-06-30 |
|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | |
| Net income per share | 0 | 0 | -0.36 | -3.69 | |
| Operating cash flow per share | 0 | 0 | -0.1 | -4.36 | |
| Free cash flow per share | 0 | 0 | -0.1 | -4.36 | |
| Cash per share | 0 | 0 | 0.18 | 0 | |
| Book value per share | 0 | 0 | 33.81 | 0 | |
| Tangible book value per share | 0 | 0 | 33.81 | 0 | |
| Share holders equity per share | 0 | 0 | 33.81 | 0 | |
| Interest debt per share | 0 | 0.02 | 0 | 1.58 | |
| Market cap | 0 | 193.62M | 40.61M | 39.7M | |
| Enterprise value | -25K | 193.83M | 39.91M | 39.7M | |
| P/E ratio | 0 | -2.5K | -7.27 | -0.7 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | |
| POCF ratio | 0 | -10.75K | -102.8 | -2.36 | |
| PFCF ratio | 0 | -10.75K | -102.8 | -2.36 | |
| P/B Ratio | 0 | 34.38K | 0.31 | 0 | |
| PTB ratio | 0 | 34.38K | 0.31 | 0 | |
| EV to sales | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | 0 | -10.01K | -28.53 | -2.69 | |
| EV to operating cash flow | 0 | -10.76K | -101.03 | -2.36 | |
| EV to free cash flow | 0 | -10.76K | -101.03 | -2.36 | |
| Earnings yield | 0 | 0 | -0.03 | -0.36 | |
| Free cash flow yield | 0 | 0 | -0.01 | -0.42 | |
| Debt to equity | 0 | 48.84 | 0 | 0 | |
| Debt to assets | 0 | 0.53 | 0 | 0 | |
| Net debt to EBITDA | 0 | -10.86 | 0.5 | 0 | |
| Current ratio | 0.24 | 0.13 | 0.13 | 0 | |
| Interest coverage | 0 | 0 | 0 | -1.42 | |
| Income quality | 0 | 0.93 | 0.28 | 1.15 | |
| Dividend Yield | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | |
| Graham number | 0 | 0 | 16.58 | 0 | |
| ROIC | 0 | -0.07 | -0.01 | 0 | |
| Return on tangible assets | 0 | -0.04 | -0.01 | 0 | |
| Graham Net | 0 | -0.03 | -1.33 | 0 | |
| Working capital | -77.14K | -443.82K | -5.07M | 0 | |
| Tangible asset value | 13.17K | 5.63K | 130.64M | 0 | |
| Net current asset value | -77.14K | -443.82K | -5.07M | 0 | |
| Invested capital | 0 | 48.84 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 3.05K | 0 | 176.37K | |
| Average inventory | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | |
| ROE | 0 | -3.44 | -0.01 | 0 | |
| Capex per share | 0 | 0 | 0 | 0 |
RACA Frequently Asked Questions
What is Therapeutics Acquisition Corp. stock symbol ?
Therapeutics Acquisition Corp. is a US stock , located in Boston of Ma and trading under the symbol RACA
What is Therapeutics Acquisition Corp. stock quote today ?
Therapeutics Acquisition Corp. stock price is $10.2743 today.
Is Therapeutics Acquisition Corp. stock public?
Yes, Therapeutics Acquisition Corp. is a publicly traded company.
Company Profile
- Volume Average 137.58K
- Market Capitalization 1.09B
- CEO Dr. Peter Kolchinsky Ph.D.
- Headquarters Boston,MA,US
- IPO Date 2020-08-07
-
Website
http://www.researchalliancecorp.com 
Therapeutics Acquisition Corp., doing business as Research Alliance Corp. I, intends to effect a merger, capital stock exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses in the healthcare industry in the United States. The company was founded in 2020 and is based in Boston, Massachusetts.
